Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 4/20 | 0.47 |
| ▸ | TNK2 | Q07912 | 2/20 | 0.41 |
| ▸ | PRMT5 | O14744 | 5/20 | 0.38 |
| ▸ | HTR1A | P08908 | 1/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.37 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.35 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.34 |
| ▸ | SCN7A | Q01118 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19202351 | 0.82 | BTK (0.57) | BTK | |
| SCHEMBL19203183 | 0.82 | BTK (0.56) | BTKTNK2PRMT5HTR1ASLC6A2 | |
| SCHEMBL19202666 | 0.81 | BTK (0.54) | BTKTNK2PRMT5MEN1KMT2A | |
| SCHEMBL19203189 | 0.79 | BTK (0.52) | BTKTNK2PRMT5KCNH2MEN1 | |
| SCHEMBL19202654 | 0.76 | BTK (0.59) | BTKTNK2PRMT5 | |
| SCHEMBL19202372 | 0.74 | BTK (0.46) | BTKTNK2PRMT5HTR1ASLC6A2 | |
| SCHEMBL19202374 | 0.72 | BTK (0.68) | BTKMEN1KMT2A | |
| SCHEMBL19203213 | 0.71 | BTK (0.54) | BTKTNK2 | |
| Hydrochloric Acid SCHEMBL31615791 | 0.71 | HTR1A (0.50) | TNK2HTR1ASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL19202349 | 0.69 | BTK (0.65) | BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10336755-B2 | Fused pyrazole derivatives, preparation method thereof, and use thereof in treatment of cancers, inflammation and immune diseases | BEIJING INNOCARE PHARMA TECH CO., LTD. (CN) | 2019-07-02 | — | — | US | disclosed |
| US-20190016721-A1 | FUSED PYRAZOLE DERIVATIVES, PREPARATION METHOD THEREOF, AND USE THEREOF IN TREATMENT OF CANCERS, INFLAMMATION AND IMMUNE DISEASES | BEIJING INNOCARE PHARMA TECH CO., LTD. (CN) | 2019-01-17 | — | — | US | disclosed |
| WO-2017128917-A1 | PARAZOLE CONDENSED-RING DERIVATIVES AND PREPARATION METHOD THEREOF AND APPLICATION THEREOF IN TREATMENT OF CANCERS, INFLAMMATION AND IMMUNE DISEASES | 北京诺诚健华医药科技有限公司 | 2017-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10336755-B2 | Fused pyrazole derivatives, preparation method thereof, and use thereof in treatment of cancers, inflammation and immune diseases | BTK, SYK, JAK1 | BTK 1/4885TNK2 328/4885PRMT5 645/4885 |
| US-20190016721-A1 | FUSED PYRAZOLE DERIVATIVES, PREPARATION METHOD THEREOF, AND USE THEREOF IN TREATMENT OF CANCERS, INFLAMMATION AND IMMUNE DISEASES | BTK, SYK, JAK1 | BTK 1/4885TNK2 328/4885PRMT5 645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.